Dyadic International (NASDAQ:DYAI) Shares Pass Below Fifty Day Moving Average – Here’s Why

Dyadic International Inc. (NASDAQ:DYAI)’s share price passed below its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of $0.78 and traded as low as $0.7550. Dyadic International shares last traded at $0.8486, with a volume of 166,010 shares.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Dyadic International in a research report on Friday, March 27th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Dyadic International presently has an average rating of “Hold” and a consensus price target of $3.00.

Dyadic International Stock Performance

The firm’s 50-day moving average is $0.78 and its 200 day moving average is $0.84. The stock has a market cap of $30.92 million, a PE ratio of -3.69 and a beta of 1.17. The company has a debt-to-equity ratio of 4.08, a quick ratio of 2.42 and a current ratio of 2.42.

Dyadic International (NASDAQ:DYAI) last released its quarterly earnings results on Wednesday, May 13th. The biotechnology company reported ($0.05) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.01). The business had revenue of $1.11 million during the quarter, compared to analysts’ expectations of $0.90 million. Dyadic International had a negative net margin of 192.40% and a negative return on equity of 1,005.45%. As a group, research analysts anticipate that Dyadic International Inc. will post 0.13 EPS for the current year.

Institutional Investors Weigh In On Dyadic International

Several institutional investors have recently made changes to their positions in DYAI. Bank of America Corp DE raised its stake in shares of Dyadic International by 16,146.7% during the 4th quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock worth $47,000 after buying an additional 26,965 shares during the last quarter. Landscape Capital Management L.L.C. acquired a new position in shares of Dyadic International during the 3rd quarter worth $190,000. Marathon Capital Management acquired a new position in shares of Dyadic International during the 3rd quarter worth $41,000. Apis Capital Advisors LLC acquired a new position in shares of Dyadic International during the 3rd quarter worth $1,817,000. Finally, Geode Capital Management LLC raised its stake in shares of Dyadic International by 13.7% during the 4th quarter. Geode Capital Management LLC now owns 301,673 shares of the biotechnology company’s stock worth $284,000 after buying an additional 36,266 shares during the last quarter. 27.95% of the stock is currently owned by hedge funds and other institutional investors.

Dyadic International Company Profile

Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.

The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.